Company: SMNR
Filing Date: 2025-03-25
Form Type: PRER14A
Source: 0001013762-25-002297
Chunk: 70

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-03-25
Form: PRER14A
Chunk 70
---
 PROXY IN THE ENVELOPE ENCLOSED. THIS PROXY, WHEN EXECUTED, WILL BE VOTED IN THE MANNER DIRECTED HEREIN. IF NO DIRECTION IS MADE, THIS PROXY WILL BE VOTED “ FOR ” PROPOSAL 1 — THE EXTENSION AMENDMENT PROPOSAL AND “ FOR ” PROPOSAL 2 — THE ADJOURNMENT PROPOSAL, IF PRESENTED. THIS PROXY WILL REVOKE ALL PRIOR PROXIES SIGNED BY YOU. THE BOARD OF DIRECTORS RECOMMENDS A VOTE “ FOR ” ALL PROPOSALS. Important Notice Regarding the Availability of Proxy Materials for the extraordinary general meeting of Shareholders to be held on [], 2025: This notice of meeting and the accompanying proxy statement are available at [].

| Proposal 1 — The Extension Amendment Proposal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |     | FOR |     | AGAINST |     | ABSTAIN |
| Amend the Company’s amended and restated memorandum and articles of association to extend the date by which the Company must either (i) consummate an initial business combination or (ii) cease its operations, except for the purpose of winding up, if it fails to complete such initial business combination and redeem 100% of the public shares from April 11, 2025 to December 11, 2025 by electing to extend the date to consummate an initial business combination on a monthly basis for up to eight (8) times by an additional one month each time, unless the closing of an initial business combination has occurred, without the need for any further approval of the Company’s shareholders, provided that the Company’s sponsor (or its affiliates or permitted designees or a third party) will deposit into the trust account necessary funds for each such one-month extension period. |     | ☐   |     | ☐       |     | ☐       |
| Proposal 2 — The Adjournment Proposal                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |     | FOR |     | AGAINST |     | ABSTAIN |
| Approve the adjournment of the extraordinary general meeting to a later date or dates, if necessary, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Extension Amendment Proposal or if the Board of Directors of the Company determines before the extraordinary general meeting that it is not necessary or no longer desirable to proceed with the other proposals